This study aims to assess the risk factors and treatment outcomes associated with neutropenia induced by Palbociclib in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study will evaluate progression-free survival (PFS) and overall survival (OS) over a two-year period, providing insights into the pharmacodynamics of Palbociclib and potential dose optimization strategies.